For written notes on this lecture, please read chapter 14 of *The Practical Bioinformatician*.

CS2220: Introduction to Computational Biology
Unit 3: Gene Expression Analysis

Wong Limsoon

NUS
National University
of Singapore

Plan

- **Microarray background**

- **Gene expression profile classification**

- **Gene expression profile clustering**

- **Normalization**

- **Extreme sample selection**

- **Gene regulatory network inference**

Background on microarrays

What is a microarray?

- **Contain large numbers of DNA molecules spotted on glass slides, nylon membranes, or silicon wafers**

- **Detect what genes are being expressed or found in a cell of a tissue sample**

- **Measure expression of thousands of genes simultaneously**

Affymetrix GeneChip®

Making Affymetrix GeneChip®

quartz is washed to ensure uniform hydroxylation across its surface and to attach linker molecules

exposed linkers become deprotected and are available for nucleotide coupling

Exercise: What is the other commonly used type of microarray? How is that one different from Affymetrix's?

Gene expression measurement by Affymetrix GeneChip®

Click to watch an interesting movie explaining the working of microarray

Total RNA

Reverse Transcription

cDNA

In Vitro Transcription

Biotin-labeled cRNA

—B
—B
—B
—B

Fragmentation

GeneChip Expression Array

Hybridization

Fragmented, Biotin-labeled cRNA

—B
—B
—B

—B
—B

—B

Wash and Stain

—B
—B
—B

Scan and Quantitate

Sample Affymetrix GeneChip® data file (U95A)

	00-0586-U9	00-0586-U9	00-0586-U9	00-0586-U9	00-0586-U9	Descriptions			
	Positive	Negative	Pairs InAvg	Avg Diff	Abs Call				
AFFX-MurI	5	2	19	297.5	A	M16762 Mouse interleukin 2 (IL-2) gene, exon 4			
AFFX-MurI	3	2	19	554.2	A	M37897 Mouse interleukin 10 mRNA, complete cds			
AFFX-MurI	4	2	19	308.6	A	M25892 Mus musculus interleukin 4 (Il-4) mRNA, comp			
AFFX-MurF	1	3	19	141	A	M83649 Mus musculus Fas antigen mRNA, complete			
AFFX-BioE	13	1	19	9340.6	P	J04423 E coli bioB gene biotin synthetase (-5, -M, -3 r			
AFFX-BioE	15	0	19	12862.4	P	J04423 E coli bioB gene biotin synthetase (-5, -M, -3 r			
AFFX-BioE	12	0	19	8716.5	P	J04423 E coli bioB gene biotin synthetase (-5, -M, -3 r			
AFFX-BioC	17	0	19	25942.5	P	J04423 E coli bioC protein (-5 and -3 represent transcr			
AFFX-BioC	16	0	20	28838.5	P	J04423 E coli bioC protein (-5 and -3 represent transcr			
AFFX-BioD	17	0	19	25765.2	P	J04423 E coli bioD gene dethiobiotin synthetase (-5 an			
AFFX-BioD	19	0	20	140113.2	P	J04423 E coli bioD gene dethiobiotin synthetase (-5 an			
AFFX-CreX	20	0	20	280036.6	P	X03453 Bacteriophage P1 cre recombinase protein (-5			
AFFX-CreX	20	0	20	401741.8	P	X03453 Bacteriophage P1 cre recombinase protein (-5			
AFFX-BioE	7	5	18	-483	A	J04423 E coli bioB gene biotin synthetase (-5, -M, -3 r			
AFFX-BioE	5	4	18	313.7	A	J04423 E coli bioB gene biotin synthetase (-5, -M, -3 r			
AFFX-BioE	7	6	20	-1016.2	A	J04423 E coli bioB gene biotin synthetase (-5, -M, -3 r			

Some advice on processing Affymetrix GeneChip® data

- **Ignore AFFX genes**
  - These genes are control genes

- **Ignore genes with "Abs Call" equal to "A" or "M"**
  - Measurement quality is suspect

- **Upperbound 40000, lowerbound 100**
  - Saturation of laser scanner

- **Deal with missing values**

Exercise: Suggest 2 ways
to deal with missing value

Type of gene expression datasets

- Gene-Conditions or **Gene-Sample** (**numeric** or discretized)

1000 - 100,000 columns

100-500 rows

	Class	Gene1	Gene2	Gene3	Gene4	Gene5	Gene6	Gene7	.....	
Sample1	Cancer	0.12	-1.3	1.7	1.0	-3.2	0.78	-0.12		
Sample2	Cancer							1.3		
.										
	~Cancer									
SampleN	~Cancer									

- Gene-Time

- Gene-Sample-Time

Type of gene expression datasets

■ Gene-Conditions or **Gene-Sample** (numeric or **discretized**)

1000 - 100,000 columns

100-500 rows

	Class	Gene1	Gene2	Gene3	Gene4	Gene5	Gene6	Gene7	.....	
Sample1	Cancer	1	0	1	1	1	0	0		
Sample2	Cancer							1		
.										
	~Cancer									
SampleN	~Cancer									

■ Gene-Time

■ Gene-Sample-Time

Application: Disease subtype diagnosis

genes →

samples ↓

benign
benign
benign
benign
malign
malign
malign
malign

???

Application: Treatment prognosis

Type of gene expression datasets

- **Gene-Conditions** or Gene-Sample (**numeric** or discretized)

**1000 - 100,000 columns**

100-500 rows

	Gene1	Gene2	Gene3	Gene 4	Gene5	Gene6	Gene7		
Cond1	0.12	-1.3	1.7	1.0	-3.2	0.78	-0.12		
Cond2							1.3		
.									
CondN									

- Gene-Time

expression level

time

- Gene-Sample-Time

(a)   (b)

Application: Drug-action detection

genes

conditions

Drug
Drug
Drug
Drug
Normal
Normal
Normal
Normal

- **Which group of genes does the drug affect? Why?**

Exercise #1

Gene expression profile classification

Childhood acute lymphoblastic leukemia subtype diagnosis

Childhood ALL

- **Major subtypes: T-ALL, E2A-PBX, TEL-AML, BCR-ABL, MLL genome rearrangements, Hyperdiploid>50**

- **Diff subtypes respond differently to same Tx**

- **Over-intensive Tx**
  - Development of secondary cancers
  - Reduction of IQ

- **Under-intensiveTx**
  - Relapse

- **The subtypes look similar**

- **Conventional diagnosis**
  - Immunophenotyping
  - Cytogenetics
  - Molecular diagnostics

- **Unavailable in most ASEAN countries**

Mission

- **Conventional risk assignment procedure requires difficult expensive tests and collective judgement of multiple specialists**

- **Generally available only in major advanced hospitals**

$\Rightarrow$ **Can we have a single-test easy-to-use platform instead?**

Overall strategy

Diagnosis of subtype → **Subtype-dependent prognosis** → **Risk-stratified treatment intensity**

- **For each subtype, select genes to develop classification model for diagnosing that subtype**

- **For each subtype, select genes to develop prediction model for prognosis of that subtype**

Subtype diagnosis by PCL

- **Gene expression data collection**

- **Gene selection by $\chi 2$**

- **Classifier training by emerging pattern**

- ~~**Classifier tuning (optional for some machine learning methods)**~~

- **Apply classifier for diagnosis of future cases by PCL**

Childhood ALL subtype diagnosis workflow

A tree-structured diagnostic workflow was recommended by our doctor collaborator

Training and testing sets

Paired datasets	Ingredients	Training	Testing
T-ALL vs OTHERS1	OTHERS1 ={E2A-PBX1, TEL-AML1, BCR-ABL, Hyperdip>50, MLL, OTHERS}	28 vs 187	15 vs 97
E2A-PBX1 vs OTHERS2	OTHERS2 = {TEL-AML1, BCR-ABL Hyperdip>50, MLL, OTHERS}	18 vs 169	9 vs 88
TEL-AML1 vs OTHERS3	OTHERS3 = {BCR-ABL Hyperdip>50, MLL, OTHERS}	52 vs 117	27 vs 61
BCR-ABL vs OTHERS4	OTHERS4 = {Hyperdip>50, MLL, OTHERS}	9 vs 108	6 vs 55
MLL vs OTHERS5	OTHERS5 = {Hyperdip>50, OTHERS}	14 vs 94	6 vs 49
Hyperdip>50 vs OTHERS	OTHERS = {Hyperdip47-50, Pseudodip, Hypodip, Normo}	42 vs 52	22 vs 27

Signal selection basic idea

- **Choose a signal w/ low intra-class distance**

- **Choose a signal w/ high inter-class distance**

Signal selection by χ2

The $\mathcal{X}^2$ value of a signal is defined as:

$$\mathcal{X}^2 = \sum_{i=1}^{m} \sum_{j=1}^{k} \frac{(A_{ij} - E_{ij})^2}{E_{ij}},$$

where m is the number of intervals, k the number of classes, A_{ij} the number of samples in the ith interval, jth class, R_i the number of samples in the ith interval, C_j the number of samples in the jth class, N the total number of samples, and E_{ij} the expected frequency of A_{ij} ($E_{ij} = R_i * C_j/N$).

Emerging patterns

- **An emerging pattern is a set of conditions**
  - usually involving several features
  - that most members of a class satisfy
  - but none or few of the other class satisfy

- **A jumping emerging pattern is an emerging pattern that**
  - some members of a class satisfy
  - but no members of the other class satisfy

- **We use only jumping emerging patterns**

Examples

Patterns	Frequency (P)	Frequency(N)
{9, 36}	38 instances	0
{9, 23}	38	0
{4, 9}	38	0
{9, 14}	38	0
{6, 9}	38	0
{7, 21}	0	36
{7, 11}	0	35
{7, 43}	0	35
{7, 39}	0	34
{24, 29}	0	34

Easy interpretation

Reference number 9: the expression of gene 37720_at > 215
Reference number 36: the expression of gene 38028_at ≤ 12

PCL: Prediction by Collective Likelihood

- Let $EP_1^P, \ldots, EP_i^P$ be the most general EPs of D^P in descending order of support.

- Suppose the test sample T contains these most general EPs of D^P (in descending order of support):

$$EP_{i_1}^P, EP_{i_2}^P, \cdots, EP_{i_x}^P$$

- Use k top-ranked most general EPs of D^P and D^N. Define the score of T in the D^P class as

$$score(T, D^P) = \sum_{m=1}^{k} \frac{frequency(EP_{i_m}^P)}{frequency(EP_m^P)}$$

- Ditto for $score(T, D^N)$.

- If $score(T, D^P) > score(T, D^N)$, then T is class P. Otherwise it is class N.

PCL learning

Top-Ranked EPs in Positive class	Top-Ranked EPs in Negative class

EP_1^P (90%)
EP_2^P (86%)
.
.
EP_n^P (68%)

EP_1^N (100%)
EP_2^N (95%)
.
.
EP_n^N (80%)

The idea of summarizing multiple top-ranked EPs is intended to avoid some rare tie cases

PCL testing

Most freq EP of pos class in the test sample

$$\text{Score}^P = EP_1^{P'} / EP_1^{P} + \ldots + EP_k^{P'} / EP_k^{P}$$

Most freq EP of pos class

Similarly,
$$\text{Score}^N = EP_1^{N'} / EP_1^{N} + \ldots + EP_k^{N'} / EP_k^{N}$$

If Score^P > Score^N, then positive class, Otherwise negative class

Accuracy of PCL (vs. other classifiers)

Testing Data	Error rate of different models			
	C4.5	SVM	NB	PCL
T-ALL vs OTHERS1	0:1	0:0	0:0	0:0
E2A-PBX1 vs OTHERS2	0:0	0:0	0:0	0:0
TEL-AML1 vs OTHERS3	1:1	0:1	0:1	1:0
BCR-ABL vs OTHERS4	2:0	3:0	1:4	2:0
MLL vs OTHERS5	0:1	0:0	0:0	0:0
Hyperdiploid>50 vs OTHERS	2:6	0:2	0:2	0:1
Total Errors	14	6	8	4

The classifiers are all applied to the 20 genes selected by $\chi 2$ at each level of the tree

Understandability of PCL

- **E.g., for T-ALL vs. OTHERS, one ideally discriminatory gene 38319_at was found, inducing these 2 EPs**

$$\{gene_{-(38\,319\_at)}@(-\infty, 15\,975.6)\} \text{ and}$$
$$\{gene_{-(38\,319\_at)}@[15\,975.6, +\infty)\}.$$

- **These give us the diagnostic rule**

If the expression of $38\,319\_at$ is less than $15\,975.6$, then this ALL sample must be a T-ALL. Otherwise it must be a subtype in OTHERS1.

Multidimensional scaling plot for subtype diagnosis

Obtained by performing PCA on the 20 genes chosen for each level

Childhood ALL cure rates

- **Conventional risk assignment procedure requires difficult expensive tests and collective judgement of multiple specialists**

$\Rightarrow$ **Not available in less advanced ASEAN countries**

Childhood ALL treatment cost

- **Treatment for childhood ALL over 2 yrs**
  – Intermediate intensity: US$60k
  – Low intensity: US$36k
  – High intensity: US$72k

- **Treatment for relapse: US$150k**

- **Cost for side-effects: Unquantified**

Current situation
(2000 new cases / yr in ASEAN)

Childhood ALL Patients Profile

- High 10%
- Low 50%
- Inter 40%

- **Intermediate intensity conventionally applied in less advanced ASEAN countries**

- **Over intensive for 50% of patients, thus more side effects**

- **Under intensive for 10% of patients, thus more relapse**

- **US$120m (US$60k * 2000) for intermediate intensity tx**

- **US$30m (US$150k * 2000 * 10%) for relapse tx**

- **Total US$150m/yr plus un-quantified costs for dealing with side effects**

Using our platform

- **Low intensity applied to 50% of patients**
- **Intermediate intensity to 40% of patients**
- **High intensity to 10% of patients**

$\Rightarrow$ **Reduced side effects**
$\Rightarrow$ **Reduced relapse**
$\Rightarrow$ **75-80% cure rates**

- **US$36m (US$36k * 2000 * 50%) for low intensity**
- **US$48m (US$60k * 2000 * 40%) for intermediate intensity**
- **US$14.4m (US$72k * 2000 * 10%) for high intensity**

- **Total US$98.4m/yr**
$\Rightarrow$ **Save US$51.6m/yr**

A nice ending…

- **Asian Innovation Gold Award 2003**

Gene expression profile clustering

Novel disease subtype discovery

Is there a new subtype?

Genes selected by χ^2

- **Hierarchical clustering of gene expression profiles reveals a novel subtype of childhood ALL**

New subtype discovered

Exercise: Name and describe one bi-clustering method

More about this in a moment

Hierarchical clustering

- **Assign each item to its own cluster**
  - If there are N items initially, we get N clusters, each containing just one item

- **Find the "most similar" pair of clusters, merge them into a single cluster, so we now have one less cluster**

- **Repeat previous step until all items are clustered into a single cluster of size N**

Gene expression profile clustering

Diagnosis via guilt-by-association

Some patient samples

genes →

samples ↓

malign
benign
benign
malign
benign
malign
benign
malign

Mr. A: ???

- **Does Mr. A have cancer?**

Let's rearrange the rows…

- **Does Mr. A have cancer?**

and the columns too…

genes

samples

benign
benign
benign
benign
malign
malign
malign
malign

Mr. A: ???

- **Does Mr. A have cancer?**

# Introduction to simple clustering methods

What is cluster analysis?

- **Finding groups of objects such that objects in a group are similar to one another and different from objects in other groups**

Intra-cluster distances are minimized

Inter-cluster distances are maximized

Notion of a cluster can be ambiguous

How many clusters?

Six Clusters

Two Clusters

Four Clusters

We can also have

K-means clustering

- **Partitional clustering approach**
- **Each cluster is associated with a centroid**
- **Each point is assigned to the cluster with the closest centroid**
- **# of clusters, K, must be specified**

1: Select K points as the initial centroids.

2: **repeat**

Assignment

3:      Form K clusters by assigning all points to the closest centroid.

4:      Recompute the centroid of each cluster.

Update

5: **until** The centroids don't change

K-means clustering illustration

Iteration 6

K-means clustering illustration

Importance of choosing initial centroids

Iteration 5

Hierarchical clustering

- **Two main types of hierarchical clustering**
  - Agglomerative:
    - **Start with the points as individual clusters**
    - **At each step, merge the closest pair of clusters until only one cluster (or k clusters) left**
  - Divisive:
    - **Start with one, all-inclusive cluster**
    - **At each step, split a cluster until each cluster contains a point (or there are k clusters)**

- **Traditional hierarchical algorithms use a similarity or distance matrix**
  - Merge or split one cluster at a time

Agglomerative hierarchical clustering

- **More popular hierarchical clustering technique**

- **Basic algorithm**

   Compute the proximity matrix

   Let each data point be a cluster

   Repeat

       Merge the two closest clusters   Merge

       Update the proximity matrix   Update

   Until only a single cluster remains

- **Key is computation of proximity of two clusters**
  - Different approaches to defining the distance / similarity between clusters

Visualization of agglomerative hierarchical clustering

Traditional Hierarchical Clustering

Traditional Dendrogram

Single, complete, & average Linkage

$$d(r,s) = \min(dist(x_{ri}, x_{sj}))$$

cluster r

cluster s

$$d(r,s) = \max(dist(x_{ri}, x_{sj}))$$

cluster s

cluster r

Single linkage defines distance betw two clusters as min distance betw them

Complete linkage defines distance betw two clusters as max distance betw them

Exercise: Give definition of "average linkage"

Image source: UCL Microcore Website

Exercise #2

Simulation: Starting situation

- **Start with clusters of individual points and a proximity matrix**

	p1	p2	p3	p4	p5	. . .
p1						
p2						
p3						
p4						
p5						
.						

Proximity Matrix

Intermediate situation

- **After some merging steps, we have some clusters**

	C1	C2	C3	C4	C5
C1					
C2					
C3					
C4					
C5					

Proximity Matrix

Copyright 2019 © Wong Limsoon

Intermediate situation

- **We want to merge the two closest clusters (C2 and C5) and update the proximity matrix.**

Proximity Matrix

After merging

- **The question is "How do we update the proximity matrix?"**

	C1	C2 U C5	C3	C4
C1		?		
C2 U C5	?	?	?	?
C3		?		
C4		?		

Proximity Matrix

C3

C4

C1

C2 U C5

p1 p2 p3 p4 p9 p10 p11 p12

How to define inter-cluster similarity?

Similarity?

	p1	p2	p3	p4	p5	. . .
p1						
p2						
p3						
p4						
p5						
.						

Proximity Matrix

- Min
- Max
- Group average
- Distance between centroids

How to define inter-cluster similarity

	p1	p2	p3	p4	p5	. . .
p1						
p2						
p3						
p4						
p5						
.						

Proximity Matrix

- **Min**
- Max
- Group average
- Distance between centroids

How to define inter-cluster similarity

	p1	p2	p3	p4	p5	. . .
p1						
p2						
p3						
p4						
p5						
.						

Proximity Matrix

- Min
- Max
- Group average
- Distance between centroids

How to define inter-cluster similarity

|	p1	p2	p3	p4	p5	. . .
p1						
p2						
p3						
p4						
p5						
.						

Proximity Matrix

- Min
- Max
- Group average
- Distance between centroids

How to define inter-cluster similarity?

	p1	p2	p3	p4	p5	. . .
p1						
p2						
p3						
p4						
p5						
.						
.						

Proximity Matrix

- Min
- Max
- Group average
- Distance between centroids

Cluster similarity: Min / single linkage

- **Similarity of two clusters is based on the two most similar (closest) points in the different clusters**

    – Determined by one pair of points, i.e., by one link in the proximity graph

	p1	p2	p3	p4	p5	p6
p1	0.00	0.24	0.22	0.37	0.34	0.23
p2	0.24	0.00	0.15	0.20	0.14	0.25
p3	0.22	0.15	0.00	0.15	0.28	0.11
p4	0.37	0.20	0.15	0.00	0.29	0.22
p5	0.34	0.14	0.28	0.29	0.00	0.39
p6	0.23	0.25	0.11	0.22	0.39	0.00

Table 8.4. Euclidean distance matrix for 6 points.

Hierarchical clustering: Min

Single-linkage clustering

Single-linkage dendrogram

Food for thought

- **What are the key strengths of single-linkage clustering?**

- **What are the key weaknesses of single-linkage clustering?**

Exercise #3

Cluster similarity: Max / complete linkage

- **Similarity of two clusters is based on the two least similar (most distant) points in the different clusters**
  - Determined by all pairs of points in the two clusters

	p1	p2	p3	p4	p5	p6
p1	0.00	0.24	0.22	0.37	0.34	0.23
p2	0.24	0.00	0.15	0.20	0.14	0.25
p3	0.22	0.15	0.00	0.15	0.28	0.11
p4	0.37	0.20	0.15	0.00	0.29	0.22
p5	0.34	0.14	0.28	0.29	0.00	0.39
p6	0.23	0.25	0.11	0.22	0.39	0.00

Table 8.4. Euclidean distance matrix for 6 points.

Hierarchical clustering: Max

Nested Clusters

Dendrogram

We still want to merge two most similar clusters each time.
But we define the distance between clusters based on MAX

Food for thought

- **What are the key strengths of complete-linkage clustering?**

- **What are the key weaknesses of complete-linkage clustering?**

Exercise #4

Cluster similarity: Group average

- **Proximity of two clusters is the average of pairwise proximity between points in the two clusters**

$$proximity(Cluster_i, Cluster_j) = \frac{\sum_{\substack{p_i \in Cluster_i \\ p_j \in Cluster_j}} proximity(p_i, p_j)}{|Cluster_i| * |Cluster_j|}$$

	p1	p2	p3	p4	p5	p6
p1	0.00	0.24	0.22	0.37	0.34	0.23
p2	0.24	0.00	0.15	0.20	0.14	0.25
p3	0.22	0.15	0.00	0.15	0.28	0.11
p4	0.37	0.20	0.15	0.00	0.29	0.22
p5	0.34	0.14	0.28	0.29	0.00	0.39
p6	0.23	0.25	0.11	0.22	0.39	0.00

Table 8.4. Euclidean distance matrix for 6 points.

Hierarchical clustering: Group average

Group Average Clustering

Group Average Dendrogram

Hierarchical clustering: Group average

- **Compromise between single and complete linkage**

- **Strengths**
  - Less susceptible to noise and outliers

- **Limitations**
  - Biased towards globular clusters

Hierarchical clustering: Comparison

Min

Max

Group average

Food for thought

- **What are the space and time complexity of hierarchical clustering?**

Exercise #5

Normalization

Sometimes, a gene expression study may involve batches of data collected over a long period of time…

Time Span of Gene Expression Profiles

Image credit: Dong Difeng

In such a case, batch effect may be severe… to the extent that you can predict the batch that each sample comes!

Image credit: Dong Difeng

⇒ **Need normalization to correct for batch effect**

Normalization approaches

- **Aim of normalization: Reduce variance w/o increasing bias**

- **Xform data so that distribution of probe intensities is same on all arrays**
  - E.g., $Z = (x - \mu) / \sigma$

- **Scaling method**
  - Intensities are scaled so that each array has same ave value
  - E.g., Affymetrix's

- **Quantile normalization**

Quantile normalization

- **Given *n* arrays of length *p*, form *X* of size *p* × *n* where each array is a column**

- **Sort each column of *X* to give X_{sort}**

- **Take means across rows of X_{sort} *and assign this* mean to each elem in the row to get X'_{sort}**

- **Get $X_{normalized}$ *by arranging each column of X'_{sort} to* have same ordering as *X***

Density of PM probe intensities for SpikeIn chips

- Implemented in some microarray s/w, e.g., EXPANDER

After quantile normalization

Figure 3.6: GEPs after the batch effects removing.

Food for thought

- **Given a cancer vs normal dataset**

- **Should you apply quantile normalization to the dataset as a whole or should you apply quantile normalization to the cancer and the normal part separately? Why?**

Density of PM probe intensities for SpikeIn chips

Exercise #6

Food for thought

- **Given a cancer vs normal dataset**

- **Should you apply Z-normalization to each phenotype separately or to the whole dataset in one go?**

- **Should you apply Z-normalization in a patient-wise or gene-wise manner? Why?**

Exercise #7

Selection of patient samples and genes for disease prognosis

Gene expression profile + clinical data ⇒ outcome prediction

- **Univariate & multivariate Cox survival analysis** (Beer et al 2002, Rosenwald et al 2002)

- **Fuzzy neural network** (Ando et al 2002)

- **Partial least squares regression** (Park et al 2002)

- **Weighted voting algorithm** (Shipp et al 2002)

- **Gene index and "reference gene"** (LeBlanc et al 2003)

- ……

Liu et al. "Use of extreme patient samples for outcome prediction from gene expression data. *Bioinformatics*, 21(16):3377--3384, 2005

Our approach

"extreme" sample selection

ERCOF

Extreme sample selection

Short-term Survivors *v.s.* Long-term Survivors

Short-term survivors
who died within a *short* period

$\Downarrow$

$F(T) < c_1$ and $E(T) = 1$

Long-term survivors
who were alive after a *long* follow-up time

$\Downarrow$

$F(T) > c_2$

T: sample
$F(T)$: follow-up time
$E(T)$: status (1:unfavorable; 0: favorable)
c_1 and c_2: thresholds of survival time

ERCOF Entropy-Based Rank Sum Test & Correlation Filtering

Flowchart text:

All features

Phase I

Fayyad's discretization algorithm based on class entropy

Remove genes with expression values w/o cut point found (can't be discretized)

Features without cut point found

Features with cut point found

Discard

Phase II

Wilcoxon Rank Sum Test w with critical values c_{lower}, c_{upper}

Calculate Wilcoxon rank sum $w(x)$ for gene x. Remove gene x if $w(x) \in$ [clower, cupper]

Features with w statistic in range [c_{lower}, c_{upper}]

F_1: features with $w < c_{lower}$; F_2: features with $w > c_{upper}$.

Discard

Group features by Pearson Correlation For each group, retain the top 50% wrt class entropy

Phase III

Subgroups construction on correlation for F_1 and F_2, respectively

Selection of representative features from each subgroups

Output representative features

Risk score construction

Linear Kernel SVM regression function

$$G(T) = \sum_i a_i y_i K(T, x(i)) + b$$

T: test sample, $x(i)$: support vector,
y_i: class label (1: short-term survivors; -1: long-term survivors)

Transformation function (*posterior probability*)

$$S(T) = \frac{1}{1 + e^{-G(T)}} \qquad (S(T) \in (0,1))$$

$S(T)$: ***risk score*** of sample T

Diffuse large B-cell lymphoma

- **DLBC lymphoma is the most common type of lymphoma in adults**

- **Can be cured by anthracycline-based chemotherapy in 35 to 40 percent of patients**
$\Rightarrow$ **DLBC lymphoma comprises several diseases that differ in responsiveness to chemotherapy**

- **Intl Prognostic Index (IPI)**
  - age, "Eastern Cooperative Oncology Group" Performance status, tumor stage, lactate dehydrogenase level, sites of extranodal disease, ...

- **Not very good for stratifying DLBC lymphoma patients for therapeutic trials**
$\Rightarrow$ **Use gene-expression profiles to predict outcome of chemotherapy?**

Rosenwald et al., *NEJM* 2002

- **240 data samples**
  - 160 in preliminary group
  - 80 in validation group
  - each sample described by 7399 microarray features

- **Rosenwald et al.'s approach**
  - identify gene: Cox proportional-hazards model
  - cluster identified genes into four gene signatures
  - calculate for each sample an outcome-predictor score
  - divide patients into quartiles according to score

Knowledge discovery from gene expression of "extreme" samples

"extreme" sample selection: < 1 yr vs > 8 yrs

knowledge discovery from gene expression

T is long-term if S(T) < 0.3

T is short-term if S(T) > 0.7

Discussions: Sample selection

Application	Data set	Status		Total
		Dead	**Alive**	
DLBCL	Original	88	72	160
	Informative	47+1(*)	25	73

Number of samples in original data and selected informative training set. (*): Number of samples whose corresponding patient was dead at the end of follow-up time, but selected as a long-term survivor.

Discussions: Gene identification

Gene selection	DLBCL
Original	4937(*)
Phase I	132(2.7%)
Phase II	84(1.7%)

Number of genes left after feature filtering for each phase.
(*): number of genes after removing those genes who were absent in more than 10% of the experiments.

Kaplan-Meier plot for 80 test cases

p-value of log-rank test: < 0.0001
Risk score thresholds: 0.7, 0.3

Improvement over IPI

(A) IPI low,
p-value = 0.0063

(B) IPI intermediate,
p-value = 0.0003

Merit of "extreme" samples

(A) W/o sample selection (*p* =0.38)

(B) With sample selection (p=0.009)

No clear difference on the overall survival of the 80 samples in the validation group of DLBCL study, if **no training sample selection conducted**

About the inventor: Huiqing Liu

- **Huiqing Liu**
  – PhD, NUS, 2004
  – Currently PI at Incyte
  – Asian Innovation Gold Award 2003
  – New Jersey Cancer Research Award for Scientific Excellence 2008
  – Gallo Prize 2008

Beyond disease diagnosis & prognosis

Beyond classification of gene expression profiles

- **After identifying the candidate genes by feature selection, do we know which ones are causal genes, which ones are surrogates, and which are noise?**

Diagnostic ALL BM samples (n=327)

Genes for class distinction (n=271)

E2A-PBX1   MLL   T-ALL   Hyperdiploid >50   BCR-ABL   Novel   TEL-AML1

-3σ -2σ -1σ 0 1σ 2σ 3σ
σ = std deviation from mean

Gene regulatory circuits

- **Genes are "connected" in "circuit" or network**

- **Expression of a gene in a network depends on expression of some other genes in the network**

- **Can we "reconstruct" the gene network from gene expression and other data?**

Source: Miltenyi Biotec

Key questions

For each gene in the network:

• **Which genes affect it?**

• **How they affect it?**
  – Positively?
  – Negatively?
  – More complicated ways?

Some techniques

- **Bayesian Networks**

  – Friedman et al., *JCB* 7:601--620, 2000

- **Boolean Networks**

  – Akutsu et al., *PSB* 2000, pages 293--304

- **Differential equations**

  – Chen et al., *PSB* 1999, pages 29--40

- **Classification-based method**

  – Soinov et al., "Towards reconstruction of gene network from expression data by supervised learning", *Genome Biology* 4:R6.1--9, 2003

A classification-based technique
Soinov et al., *Genome Biology* 4:R6.1-9, 2003

- **Given a gene expression matrix X**
  - each row is a gene
  - each column is a sample
  - each element x_{ij} is expression of gene i in sample j

- **Find the average value a_i of each gene i**

- **Denote s_{ij} as state of gene i in sample j,**
  - s_{ij} = up if $x_{ij} > a_i$
  - s_{ij} = down if $x_{ij} \leq a_i$

A classification-based technique
Soinov et al., *Genome Biology* 4:R6.1-9, Jan 2003

- **To see whether the state of gene g is determined by the state of other genes**

  – See whether $\langle s_{ij} \mid i \neq g \rangle$ can predict s_{gj}

  – If can predict with high accuracy, then "yes"

  – Any classifier can be used, such as C4.5, PCL, SVM, etc.

- **To see how the state of gene g is determined by the state of other genes**

  – Apply C4.5 (or PCL or other "rule-based" classifiers) to predict s_{gj} from $\langle s_{ij} \mid i \neq g \rangle$

  – Extract the decision tree or rules used

Advantages of this method

- **Can identify genes affecting a target gene**

- **Don't need discretization thresholds?**

- **Each data sample is treated as an example**

- **Explicit rules can be extracted from the classifier (assuming C4.5 or PCL)**

- **Generalizable to time series**

- **Discuss the point "Don't need discretization thresholds". Is it true?**

Exercise #8

Concluding remarks

Bcr-Abl

- **Targeted drug dev**
  - Know what molecular effect you want to achieve
    - **E.g., inhibit a mutated form of a protein**
  - Engineer a compound that directly binds and causes the desired effect

- **Gleevec (imatinib)**
  - 1st success for real drug
  - Targets Bcr-Abl fusion protein (ie, Philadelphia chromosome, Ph)
  - NCI summary of clinical trial of imatinib for ALL at

  http://www.cancer.gov/clinicaltrials/results/ALLimatinib1109/print

What have we learned?

- **Technologies**
  - Microarray
  - PCL, ERCOF

- **Microarray applications**
  - Disease diagnosis by supervised learning
  - Subtype discovery by unsupervised learning
  - Disease diagnosis via guilt-by-association
  - Gene network reconstruction

- **Important tactic**
  - Extreme sample selection

Useful packages

- **EXPANDER (EXPression Analyser & DisplayER)**
  - http://acgt.cs.tau.ac.il/expander

- **BRB-Array Tools**
  - http://linus.nci.nih.gov/BRB-ArrayTools.html

- **NetProt**
  - http://rpubs.com/gohwils/204259
  - https://github.com/gohwils/NetProt/releases/

Any question?

References

- E.-J. Yeoh et al., "Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling", *Cancer Cell*, 1:133--143, 2002

- H. Liu, J. Li, L. Wong. Use of Extreme Patient Samples for Outcome Prediction from Gene Expression Data. *Bioinformatics*, 21(16):3377--3384, 2005.

- L.D. Miller et al., "Optimal gene expression analysis by microarrays", *Cancer Cell* 2:353--361, 2002

- J. Li, L. Wong, "Techniques for Analysis of Gene Expression", *The Practical Bioinformatician*, Chapter 14, pages 319—346, WSPC, 2004

- B. Bolstad et al. "A comparison of normalization methods for high density oligonucleotide array data based on variance and bias". *Bioinformatics*, 19:185–193. 2003